IBRX
HEALTHCAREImmunityBio Inc
$8.38+0.80 (+10.55%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IBRX Today?
No stock-specific AI insight has been generated for IBRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.95$12.43
$8.38
Fundamentals
Market Cap$8.8B
P/E Ratio—
EPS$-0.38
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume19.6M
Avg Volume (10D)—
Shares Outstanding1.05B
IBRX News
65 articles- Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan FoxThe Globe and Mail·May 7, 2026
- IBRX stock enters heavy catalyst phase: Traders brace for key Anktiva decision amid Trump’s FDA turmoilMSN·May 7, 2026
- ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 MillionYahoo Finance·May 7, 2026
- High Insider Ownership Growth Stocks To Watch In May 2026Yahoo Finance·May 5, 2026
- ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual MeetingYahoo Finance·May 5, 2026
- ImmunityBio FDA Warning And Lawsuits Test Anktiva Growth StoryYahoo Finance·May 4, 2026
- ImmunityBio to Report Q1 Earnings: What's in the Cards?Yahoo Finance·May 4, 2026
- Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue GrowthYahoo Finance·May 2, 2026
- IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·May 1, 2026
- ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 29, 2026
- Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Apr 29, 2026
- INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 28, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc.·Apr 28, 2026
- What Makes ImmunityBio (IBRX) a New Buy StockYahoo Finance·Apr 27, 2026
- Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 26, 2026
- ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff DeadlineGlobeNewswire Inc.·Apr 25, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc.·Apr 25, 2026
- IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitGlobeNewswire Inc.·Apr 25, 2026
- Does Saudi ANKTIVA Launch Signal a New Phase in ImmunityBio’s (IBRX) Commercial Strategy?Yahoo Finance·Apr 24, 2026
- ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi ArabiaYahoo Finance·Apr 24, 2026
- IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens BermanGlobeNewswire Inc.·Apr 23, 2026
- Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 22, 2026
- Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Apr 22, 2026
- ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 22, 2026
- Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look”Yahoo Finance·Apr 21, 2026
- ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA PartnershipYahoo Finance·Apr 21, 2026
- IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misled on Drug Efficacy: Levi & KorsinskyGlobeNewswire Inc.·Apr 20, 2026
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CIGLGlobeNewswire Inc.·Apr 19, 2026
- ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc.·Apr 19, 2026
- ImmunityBio (IBRX) Global Expansion Bolsters 266% Jump This YearYahoo Finance·Apr 17, 2026
- ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc.·Apr 17, 2026
- ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 15, 2026
- Assessing ImmunityBio (IBRX) Valuation After ANKTIVA Driven Q1 2026 Revenue UpdateYahoo Finance·Apr 14, 2026
- ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA MomentumYahoo Finance·Apr 13, 2026
- IBRX Stock Rises 7% on Strong Q1 2026 Preliminary ResultsYahoo Finance·Apr 10, 2026
- ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable SecuritiesYahoo Finance·Apr 9, 2026
- IBRX Responds to FDA Warning Over Misleading Cancer Drug ClaimsYahoo Finance·Apr 7, 2026
- Is ImmunityBio’s (IBRX) FDA Promotion Setback Reframing the Stock’s Risk and Credibility Narrative?Yahoo Finance·Apr 7, 2026
Price Data
Open$7.70
Previous Close$7.58
Day High$8.39
Day Low$7.67
52 Week High$12.43
52 Week Low$1.95
52-Week Range
$1.95$12.43
$8.38
Fundamentals
Market Cap$8.8B
P/E Ratio—
EPS$-0.38
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume19.6M
Avg Volume (10D)—
Shares Outstanding1.05B
About ImmunityBio Inc
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—